Monoclonal Antibodies
Dose 1 for Diabetic Macular Edema
Abilene, TX, Abilene, TX
Targeting 2 different conditionsEYE103Phase 1 & 2RecruitingResearch Sponsored by EyeBiotech Ltd.Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be willing and able to understand the study procedures and the risks involved and provide written informed consent before the first study-related activity
DME patients must be ≥ 18 years of age, NVAMD patients must be ≥ 50 years of age
Must not have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow ups3 months
Awards & highlights
No Placebo-Only Group
Study Summary
This trial tests a potential drug to help people with vision problems caused by diabetes or macular degeneration. It will assess its safety and effectiveness.
Eligible Conditions
- Diabetic Macular Edema
- Age-related Macular Degeneration (AMD)
Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow ups ~ 3 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow ups ~ 3 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Adverse Events
Secondary outcome measures
Best-corrected Visual Acuity
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
10Treatment groups
Experimental Treatment
Group I: Naïve NVAMD Medium DoseExperimental Treatment1 Intervention
Part 2 Naïve NVAMD combination therapy Medium Dose
Group II: Naïve NVAMD High DoseExperimental Treatment1 Intervention
Part 2 Naïve NVAMD combination therapy High Dose
Group III: Experienced NVAMD Medium DoseExperimental Treatment1 Intervention
Part 2 Experienced NVAMD combination therapy Medium Dose
Group IV: Experienced NVAMD High DoseExperimental Treatment1 Intervention
Part 2 Experienced NVAMD combination therapy High Dose
Group V: Dose 4Experimental Treatment1 Intervention
Part 1 MAD Portion Dose 4 - High Dose
Group VI: Dose 3Experimental Treatment1 Intervention
Part 1 MAD Portion Dose 3 - Mid-High Dose
Group VII: Dose 2Experimental Treatment1 Intervention
Part 1 MAD Portion Dose 2 - Low-Mid Dose
Group VIII: Dose 1Experimental Treatment1 Intervention
Part 1 MAD Portion Dose 1 - Low Dose
Group IX: DME Medium DoseExperimental Treatment1 Intervention
Part 2 Naïve DME monotherapy Medium Dose
Group X: DME High DoseExperimental Treatment1 Intervention
Part 2 Naïve DME monotherapy High Dose
Find a site
Who is running the clinical trial?
EyeBiotech Ltd.Lead Sponsor
Media Library
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
How many individuals are partaking in this research endeavor?
"This research requires 92 qualified individuals to participate. Recruitment extends across Lemont, Illinois and Reno, Nevada with sites located in those respective cities."
Answered by AI
Are there any openings for participants in this trial?
"The trial's profile on clinicaltrials.gov affirms that enrolment is still open; the study was initially posted June 12th 2023 and its most recent update occurred two days later, on June 14th of the same year."
Answered by AI
How far-reaching is the availability of this trial?
"This study is currently recruiting patients at 5 distinct sites, such as Lemont in Nevada and Reno in Nevada. Additionally, Germantown located in Tennessee serves as another recruitment centre, with a further five locations also participating."
Answered by AI